Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium (NiCCC)
A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
Sponsor: ARCAGY/ GINECO GROUP
Listed as NCT02866370, this PHASE2 trial focuses on Endometrial Clear Cell Carcinoma and Ovarian Clear Cell Carcinoma and remains ongoing. Sponsored by ARCAGY/ GINECO GROUP, it has been updated 6 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ARCAGY/ GINECO GROUP
- Boehringer Ingelheim
- Cancer Research UK
- European Organisation for Research and Treatment of Cancer - EORTC
- NHS Greater Glasgow and Clyde
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
For direct contact, visit the study record on ClinicalTrials.gov .